US CMS CONFIRMS OUTPATIENT REIMBURSEMENT RATES FOR 2027

Highlights

- US CMS confirms the existing payment rate of **US$127.14 per square centimetre** of wound area treated in outpatient settings for AROA ECM™ sheet products will continue in 2027, providing reimbursement stability and certainty.
- From **1 January 2027**, the payment rate of **US$127.14 per square centimetre** will also apply to non-sheet products in physician's offices.

Soft tissue regeneration company Aroa Biosurgery Limited (ASX: ARX, 'AROA' or the 'Company') provides an update on the United States Centers for Medicare & Medicaid Services' (CMS) final reimbursement rules for calendar year 2027 published on 4 November.

AROA's primary focus remains Myriad in the hospital inpatient setting, where reimbursement is well established and unaffected by these outpatient changes. Recent changes in outpatient reimbursement support the opportunity for Symphony™.

The final reimbursement rules for 2027 maintain the existing payment rate for Symphony and introduce a standard national payment rate for non-sheet products in physician offices.

Continued reimbursement stability for Symphony

Consistent with the proposed framework outlined in AROA's 14 July 2026 announcement, the payment rate for Symphony will remain at US$127.14 per square centimetre of wound area treated in hospital outpatient departments, ambulatory surgical centres, and physician offices.

AROA believes that Symphony's responsible pricing, supported by its recently published randomised controlled trial, positions it well for adoption in the outpatient setting. The continuation of the payment framework provides greater certainty as AROA pursues this opportunity.

New payment arrangements for non-sheet products in physician's offices

From 1 January 2027, a national product payment rate of US$127.14 per square centimetre will apply to non-sheet products in physician's offices. Payment is based on the wound area treated in square centimetres. This creates a new opportunity for morcellised versions of AROA ECM™.

AROA Founder and CEO Brian Ward said:

"We welcome the greater payment certainty these rules provide for healthcare providers and hospitals following significant change in outpatient reimbursement. Symphony is well positioned in this environment, supported by compelling clinical evidence and responsible pricing."

<ENDS>

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

AROA BIOSURGERY LIMITED
ARBN 638 867 473 NZCN 1980577
64 Richard Pearse Drive, Auckland 2022, New Zealand
AROA.COM

Contact

investor@aroa.com

About AROA™
Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for every*body*'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix bioscaffold derived from ovine (sheep) forestomach. Over 7.5 million AROA devices have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELABio, Inc. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). www.aroa.com